Selected article for: "progressive disease and stable disease"

Title: 2016 ACVIM Forum Research Abstract Program
  • Document date: 2016_5_31
  • ID: 2y1y8jpx_207
    Snippet: Results: Eleven dogs were enrolled to obtain the maximum tolerated dose (MTD). A total of twenty seven dogs were enrolled to further investigate toxicity and tumor response. The Folate-Tubulysin MTD was 0.26 mg/kg administered every two weeks. The most common DLTs were neutropenia, anorexia, and/or lethargy. Resolution of side effects occurred with minimal supportive care and in some dogs treatment delay. Early categorical tumor responses have in.....
    Document: Results: Eleven dogs were enrolled to obtain the maximum tolerated dose (MTD). A total of twenty seven dogs were enrolled to further investigate toxicity and tumor response. The Folate-Tubulysin MTD was 0.26 mg/kg administered every two weeks. The most common DLTs were neutropenia, anorexia, and/or lethargy. Resolution of side effects occurred with minimal supportive care and in some dogs treatment delay. Early categorical tumor responses have included 3 partial remissions, 16 stable disease, 8 progressive disease.

    Search related documents: